dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· November 3, 2025

BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung

View original at globenewswire.com
“Nettogewinn / (-verlust) (28,7) 198,1 (831,1) (924,8)”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pumitamig showed encouraging anti-tumor activity, positive PFS trend, controlled safety profile, and low discontinuation rate in ES-SCLC Phase 2 trial

    80% confidence

  • BioNTech expects no positive net income for FY 2025

    80% confidence

  • ROSETTA Breast-01 Phase 3 trial for TNBC will start by end of 2025

    80% confidence

  • Trastuzumab Pamirtecan BLA filing planned for 2026 pending FDA feedback

    80% confidence

  • Autogene Cevumeran showed strong durable immune responses up to 1.5 years post-treatment with broad immune response correlated with extended PFS

    80% confidence

  • BNT111 demonstrated deep durable antitumor responses with statistically significant improvement in ORR vs historical control

    80% confidence

  • 2025 CapEx expected to be €200-250M, reduced from previous guidance of €250-350M

    80% confidence

  • 2025 revenue guidance is €2,600-2,800M

    80% confidence

  • 2025 SG&A costs expected to be €550-650M, reduced from previous guidance of €650-750M

    80% confidence

  • 2025 R&D costs expected to be €2,000-2,200M, reduced from previous guidance of €2,600-2,800M

    80% confidence

Data points we hold from this source

BioNTech SE · outstanding shares240455450 shares
BioNTech SE · r and d costs564.8 million_EUR
BioNTech SE · sg and a costs148.5 million_EUR
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Un éditeur vérifie les conflits entre sources avant de les publier ici.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com

Données de travail, pas l’article final. Voici ce que notre IA a lu et extrait des documents sources jusqu’ici. Notre méthode

BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung: Source | Via News | fr.via.news